New drug duo aims to control CLL without lifelong treatment
NCT ID NCT07508995
First seen Apr 24, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This phase 2 trial tests two experimental drugs, BGB-16673 and sonrotoclax, given together for a limited time in 40 people with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can control the disease. Participants take both drugs by mouth, and the study will monitor side effects and how well the leukemia responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BGB-16673 and sonrotoclax
What this could lead to
If successful, this could offer a new, time-limited treatment option for people with untreated CLL, potentially controlling the disease without lifelong therapy.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The combination may cause side effects or not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.